BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 18397827)

  • 1. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
    Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
    Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
    Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of rigid trichostatin A analogs as HDAC inhibitors.
    Charrier C; Bertrand P; Gesson JP; Roche J
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5339-44. PubMed ID: 16904890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
    Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
    Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
    Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues.
    Kim SA; Jin YL; Kim HS
    Arch Pharm Res; 2009 Jan; 32(1):15-21. PubMed ID: 19183872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
    Kim HM; Hong SH; Kim MS; Lee CW; Kang JS; Lee K; Park SK; Han JW; Lee HY; Choi Y; Kwon HJ; Han G
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6234-8. PubMed ID: 17904843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
    Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
    Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
    Dehmel F; Ciossek T; Maier T; Weinbrenner S; Schmidt B; Zoche M; Beckers T
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4746-52. PubMed ID: 17606370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
    Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
    J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
    Charrier C; Roche J; Gesson JP; Bertrand P
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6142-6. PubMed ID: 17897824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
    Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
    Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.